pharmaphorum

SEPTEMBER 9, 2022

Prior to the launch of those drugs, pharmacological therapy for obesity was something of a backwater, constrained by tolerability and safety issues for older, generic drugs, and lacklustre take-up of newer therapies with limited efficacy. Novo Nordisk recently predicted its obesity sales could reach $3.7 billion in 2025.

Pharmacology 95

Pharmacology Patients Management Consulting 95

European Pharmaceutical Review

JULY 13, 2023

While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.

Medical 85

Medical Food and Drug Administration Pharmacology Medicine 85

pharmaphorum

JANUARY 17, 2023

Angion chalked up a series of trial failures for its hepatocyte growth factor (HGF) mimetic ANG-3777 over the last couple of years, and turned its attention to tyrosine kinase receptor inhibitor ANG-3070 in kidney diseases and fibrotic disorders, before abandoning the drug due to safety concerns in the middle of 2022.

Pharmacology 72

Pharmacology Engineering Consulting Leads 72

European Pharmaceutical Review

DECEMBER 11, 2023

mAbs have well-established safety profiles, high specificity and affinity and long half-lives – they have been used in drug development for more than 30 years. Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities.

Pharmacology 84

Pharmacology Safety Engineering Medical 84

European Pharmaceutical Review

SEPTEMBER 22, 2023

7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.

Food and Drug Administration 78

Food and Drug Administration Safety Patients Leads 78

Pharmaceutical Technology

OCTOBER 10, 2022

Despite the recognized need and demand for options to treat female sexual dysfunction, several safety and access issues associated with the use of available options. All this development comes in the backdrop of a wider sense of stigma against the use of pharmacologic options for female sexual function, says Kingsberg.

Pharmacology 59

Pharmacology Side effects FDA Safety 59

Pharmaceutical Technology

FEBRUARY 17, 2023

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The clinical pharmacology knowledge also isn’t present at smaller companies, he adds.

FDA 115

FDA Side effects Pharmacology Patients 115